Finland · Delayed Price · Currency is EUR Terveystalo Oyj Earnings Call Transcripts
Fiscal Year 2026
-
A major acquisition will create a leading European outpatient care platform, combining complementary strengths in healthcare and eye care, with strong financials, significant synergies, and robust shareholder support. The deal accelerates growth, diversifies revenue, and positions the group for future innovation and expansion.
-
Revenue and profitability declined sharply in Q1 2026 amid an exceptionally weak healthcare market, but operational efficiency and digital investments remained strong. Management expects gradual recovery from H2, with full-year EBIT guidance maintained and key growth initiatives underway.
Fiscal Year 2025
-
All-time high profitability and efficiency achieved despite revenue declines and market headwinds. 2026 guidance reflects a wide range due to macro and seasonal uncertainties, with investments in digital transformation and M&A supporting future growth.
-
Q3 delivered improved margins and strong cash flow despite a 5% revenue decline, with Sweden and portfolio businesses showing efficiency gains. Guidance for adjusted EBIT is maintained at EUR 155–165 million, and digital investments and M&A activity are set to drive future growth.
-
Record Q2 EBIT and margin achieved despite lower revenue, driven by efficiency gains and improved profitability across all segments. Outlook for H2 is positive, supported by the Kela 65 pilot, public sector demand, and ongoing digitalization initiatives.
-
Q1 saw strong profitability gains with adjusted EBIT up 20% and EPS up 40% year-over-year, despite a slight revenue decline due to softness in Sweden and outsourcing contract expiries. Guidance for 2025 is reiterated, with growth and margin improvement expected.
Fiscal Year 2024
-
Record financial and quality results in 2024, with strong revenue and EBITDA growth, improved margins, and robust cash flow. Guidance for 2025 targets further margin and EPS growth, supported by ongoing efficiency and technology investments.
-
Turnaround has been delivered ahead of schedule, with a structurally stronger, less risky business and a confident shift to balanced, organic growth. Digitalization, integrated care, and targeted investments drive profitability, while new financial targets focus on 10% EPS growth and high dividends.
-
A leading Nordic healthcare provider reported strong profitability and growth, driven by digital integration, operational improvements, and resilience in a challenging market. Future plans focus on incremental growth, technology investment, and leveraging demographic and funding trends.
-
Q3 delivered record profitability and strong revenue growth, with Healthcare Services leading margin gains and Portfolio Businesses improving despite revenue declines. The turnaround phase is complete ahead of schedule, and focus shifts to growth and investment, supported by robust cash flow and financial flexibility.
-
Q2 marked a record quarter with 5% revenue growth, 50% higher adjusted EBITDA, and a 91% EPS increase, led by Healthcare Services. Updated guidance expects 11.5–12.5% EBITDA margin for 2024, with strong cash flow and continued operational improvements across segments.